Navigation Links
Vanda Pharmaceuticals Responds to Announcement and Filing by a Group Led by Tang Capital Partners, LP
Date:2/23/2009

of liquidation by all stockholders, which, given the Board's perspective, is extremely unlikely. The Company's Board of Directors has determined that it remains to be in the best interests of the Company to continue its operations.

Vanda has previously met with TCP to discuss its proposals and would be willing to meet with them again in the future.

ABOUT VANDA PHARMACEUTICALS INC.:

Vanda Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this release are "forward-looking statements" under the securities laws. Words such as, but not limited to, "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," and "could," and similar expressions or words, identify forward-looking statements. Forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in the company's forward-looking statements include, among others: delays in the completion of Vanda's clinical trials; a failure of Vanda's product candidates to be demonstrably safe and effective; Vanda's failure to obtain regulatory approval for its products or to comply with ongoing regulatory requirements; a lack of acceptance of Vanda's product candidates in the marketplace, or a failure to become or remain profitable; Vanda's inability to obtain the c
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine news :

1. FDA Accepts Vanda Pharmaceuticals Iloperidone Resubmission and Sets New Action Date
2. Vanda Pharmaceuticals Announces Receipt of Not Approvable Letter From FDA for Iloperidone
3. Vanda Pharmaceuticals to Present at the FBR Capital Markets 12th Annual Spring Investor Conference
4. Vanda Pharmaceuticals Announces that it No Longer Intends to Offer Convertible Senior Notes
5. Vanda Pharmaceuticals VSF-173 Excessive Sleepiness Phase II Clinical Trial Suggests Wake-Promoting Properties
6. Vanda Pharmaceuticals to Announce Third Quarter 2007 Financial Results on November 8, 2007
7. Vanda Pharmaceuticals to Present New Data on Iloperidone at the 2007 American Society of Human Genetics Annual Meeting
8. Vanda Pharmaceuticals to Present at Natixis Bleichroeders Hidden Gems Conference
9. Onyx Pharmaceuticals Reports Record Full Year and Fourth Quarter 2008 Financial Results
10. Nostrum Pharmaceuticals Obtains Worldwide Licensing Rights From IMTECH for Clinical Development of the Small Molecule Caerulomycin and Its Proprietary Derivatives for Their Novel Indication of Immunosuppression
11. Anadys Pharmaceuticals to Report Fourth Quarter and Year End 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... HeartMath® Inc., recognized as one ... rate variability (HRV), heart coherence and the physiology ... databases and algorithms to chipset manufacturers and consumer ... partners to offer its HRV solutions, tap into ... as its normative HRV databases and algorithms for ...
(Date:12/17/2014)... 2014 In its comprehensive analysis of ... Argus Claim Review division have recently identified out-of-network and ... ways savings are achieved on behalf of employer-clients. ... dollars in savings to Argus each year, with a ... explained by Tom Doney, Cypress president and CEO, these ...
(Date:12/17/2014)... 2014 Now in its second year, ... of the best in senior living and home care ... to communities and agencies that have received outstanding online ... the nearly 100,000 providers currently listed on SeniorAdvisor.com, only ... SeniorAdvisor.com Best of 2015 Awards are located all over ...
(Date:12/17/2014)... 2014 (HealthDay News) -- As gas prices rose in ... new study suggests. In times of gas increases, ... riders are inexperienced, the researchers explained. They examined ... has the highest number of motorcycle registrations in the ... deaths. The analysis revealed a strong association between ...
(Date:12/17/2014)... TUESDAY, Dec. 16, 2014 (HealthDay News) -- Expectant parents ... Food and Drug Administration recommends. Use of ultrasound ... videos is not entirely risk-free, the agency warns. ... any harm due to ultrasound imaging and heartbeat monitors, ... providers is important," Shahram Vaezy, an FDA biomedical engineer, ...
Breaking Medicine News(10 mins):Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 2Health News:HeartMath® Inc.’s HRV Platform Solutions Available for Licensing 3Health News:Out-of-Network & Medical Necessity Reviews among Top Ways TPA Identifies Significant Medical Claim Savings 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 2Health News:The Inn at Willow Falls - Crest Hill, IL Wins 2015 Best of Assisted Living Award from SeniorAdvisor.com 3Health News:When Gas Prices Go Up, So Do Motorcycle Accidents, Study Finds 2Health News:FDA Warns Against Fetal 'Keepsake' Videos 2
... of $5.2 Million Lifted, SALT LAKE CITY, ... ), the only U.S.-based publicly traded manufacturer of,digital ... subsidiary,successfully negotiated an amendment with Commerzbank AG, a ... acquisition of the German subsidiary. The,amendment resulted in ...
... but researchers from Tel Aviv University have found good reasons ... Dr. Liran Levin, a dentist from the Department of Oral ... found that about 15 to 20 percent of teens with ... and gum disease. Resulting tooth fractures as well as periodontal ...
... of Physicians (ACP) today commended the Medicare Payment Advisory ... primary care in a well-functioning health-care delivery system in ... MedPAC in a letter to Glen D. Hackbarth, chairman ... the U.S. Congress on issues affecting the Medicare program. ...
... boys , , FRIDAY, June 20 (HealthDay News) -- Summer ... is gearing up to warn players and their fans ... Baseball, the Major League Baseball Players Association and the ... 10th annual Play Sun Smart campaign on that day, ...
... 20 A team of medical,professionals from the ... services in Germany impressive. The NRH team has ... the US Army,s Europe Regional,Medical Command (ERMC) in ... and capability of our military health care system ...
... . , Finger ring dosemeters are used at diverse ... order to check whether the effective dose limt values are ... been subjected to an annual quality control by the PTB ... in Germany have passed these controls. , In Germany, ...
Cached Medicine News:Health News:Sonic Innovations Announces Loan Amendment With German Bank 2Health News:Sonic Innovations Announces Loan Amendment With German Bank 3Health News:Warning for teens: Teeth and jewelry don't mix 2Health News:American College of Physicians commends MedPAC June 2008 report to Congress 2Health News:American College of Physicians commends MedPAC June 2008 report to Congress 3Health News:Pro Baseball Helps Keep Skin Cancer From Scoring 2Health News:Pro Baseball Helps Keep Skin Cancer From Scoring 3Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 2Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 3Health News:National Rehabilitation Hospital Team Calls Work of US Army's Europe Regional Medical Command Impressive 4Health News:PTB testing method for finger ring dosemeters has proven its effectiveness 2
(Date:12/17/2014)... 2014  Beamz Interactive, Inc. (OTCQB: BZIC), a ... announced that it has signed an agreement with ... of innovative prosthetic, orthotic and assistive technology products ... agreement, RSL Steeper will promote and supply the ... use within UK residential care facilities through its ...
(Date:12/17/2014)... 17, 2014  ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE ... Trademark Office (USPTO) has issued a key patent ... immunotherapeutic vaccine targeting six tumor antigens that are ... Patent No. 8,871,211, which issued October 28, 2014, ... a dendritic cell composition comprising peptide epitopes of ...
(Date:12/17/2014)... MARLBOROUGH, Mass. , Dec. 17, 2014 /PRNewswire/ ... a biotechnology company focused on discovering, developing and ... using RNA-targeted technologies, today announced completion of enrollment in ... results from the 3-month observations confirmed the 1-month ... year:  Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO ...
Breaking Medicine Technology:Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 2Beamz Interactive, Inc. Signs UK Distribution Agreement with RSL Steeper Limited 3ImmunoCellular Therapeutics Announces Issuance of Key Patent For ICT-107 Cancer Vaccine 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5
... YORK, March 31, 2011 Intercept Pharmaceuticals, Inc., today ... double-blind  Phase II clinical trial of obeticholic acid (OCA) ... (PBC).  The study evaluated the effects of 10 mg ... patients with elevated alkaline phosphatase (AP).  AP is a ...
... Services Corp., a leading provider of pharmaceutical product ... of Dean Shirazi, Ph.D., to Vice President, Analytical ... 4, 2011. (Logo:   https://photos.prnewswire.com/prnh/20110330/CG74146LOGO ) ... in June 1992 as a Senior Scientist, has ...
Cached Medicine Technology:Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis 2Intercept Pharmaceuticals Announces Positive Phase II Results for Obeticholic Acid (INT-747) as Monotherapy in Primary Biliary Cirrhosis 3AAIPharma Services Announces Promotion of Dean Shirazi 2
10% Casein digest (NZ amine), 5.0% Sodium Chloride, 5.0% Yeast Extract....
0.5% Yeast Extract, 2.0% Tryp, 10mM Sodium Chloride, 2.5mM Potassium Chloride....
S.O.C. Medium...
... rHead Radial Implant System provides todays ... to radial head replacement. Modular ... patient anatomy while minimizing ligamentous and ... designed alignment guide assists in both ...
Medicine Products: